Search

Your search keyword '"Cathomas R"' showing total 364 results
Start Over Author "Cathomas R"
364 results on '"Cathomas R"'

1. Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs

Author

Turco F, Gillessen S, Cathomas R, Buttigliero C, and Vogl UM

Subjects
prostate cancer – castration resistant prostate cancer – non metastatic castration resistant prostate cancer – metastatic castration resistant prostate cancer - treatment landscape in prostate cancer, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Fabio Turco,1,2 Silke Gillessen,1,3 Richard Cathomas,4 Consuelo Buttigliero,2 Ursula Maria Vogl1 1IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; 2Department of Oncology, University of Turin, at Division of Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Turin, 10043, Italy; 3Universita della Svizzera Italiana, Lugano, Switzerland; 4Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, SwitzerlandCorrespondence: Fabio Turco, IOSI (Oncology Institute of Southern Switzerland), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland, Tel +39 3927704290, Fax +41 0918119061, Email turcofabio9@gmail.comAbstract: Metastatic castration resistant prostate cancer (CRPC) is an inevitably fatal disease. However, in recent years, several treatments have been shown to improve the outcome of CRPC patients both in the non-metastatic (nmCRPC) as well as the metastatic setting (mCRPC). In nmCRPC patients with a PSA doubling time < 10 months, the addition of enzalutamide, apalutamide and darolutamide to androgen deprivation therapy (ADT) compared to ADT alone resulted in improved metastases free (MFS) and overall survival (OS). For mCRPC patients, several treatment options have been shown to be effective: two taxane based chemotherapies (docetaxel and cabazitaxel), two androgen-receptor pathway inhibitors (ARPI) (abiraterone and enzalutamide), two radiopharmaceutical agents (radium 223 and 177Lutetium-PSMA-617), one immunotherapy treatment (sipuleucel-T) and two poly ADP-ribose polymerase (PARP) inhibitors (olaparib and rucaparib). Pembrolizumab is US Food and Drug Administration (FDA) approved in all MSI high solid tumors, although a very small proportion of prostate cancer patients harboring this characteristic will benefit. Despite having a broad variety of treatments available, there are still several unmet clinical needs for CRPC. The objective of this review was to describe the therapeutic landscape in CRPC patients, to identify criteria for selecting patients for specific treatments currently available, and to address the current challenges in this setting.Keywords: prostate cancer, castration resistant prostate cancer, non-metastatic castration resistant prostate cancer, metastatic castration resistant prostate cancer

Published
2022

2. Real world evidence from a retrospective multi-center analysis for the combination immunotherapy ipilimumab and nivolumab as first-line treatment in advanced renal cell carcinoma

Author

Materna, L., primary, Schlack, K., additional, Stelmach, R., additional, Zschäbitz, S., additional, Neuberger, S., additional, Aydogdu, C., additional, Casuscelli, J., additional, Egenolf, T., additional, Silberg, M., additional, Steinestel, J., additional, Strauss, A., additional, Kirchhoff, F., additional, Ahrens, M., additional, Paffenholz, P., additional, Cathomas, R., additional, Gossler, C., additional, Ivanyi, P., additional, Rehlinghaus, M., additional, Hilser, T., additional, and Grünwald, V., additional

Published
2023
Full Text
View/download PDF

3. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A., Babjuk, M., Bellmunt, J., Bruins, H.M., De Reijke, T.M., De Santis, M., Gillessen, S., James, N., Maclennan, S., Palou, J., Powles, T., Ribal, M.J., Shariat, S.F., Van Der Kwast, T., Xylinas, E., Agarwal, N., Arends, T., Bamias, A., Birtle, A., Black, P.C., Bochner, B.H., Bolla, M., Boormans, J.L., Bossi, A., Briganti, A., Brummelhuis, I., Burger, M., Castellano, D., Cathomas, R., Chiti, A., Choudhury, A., Compérat, E., Crabb, S., Culine, S., De Bari, B., DeBlok, W., De Visschere, P.J.L., Decaestecker, K., Dimitropoulos, K., Dominguez-Escrig, J.L., Fanti, S., Fonteyne, V., Frydenberg, M., Futterer, J.J., Gakis, G., Geavlete, B., Gontero, P., Grubmüller, B., Hafeez, S., Hansel, D.E., Hartmann, A., Hayne, D., Henry, A.M., Hernandez, V., Herr, H., Herrmann, K., Hoskin, P., Huguet, J., Jereczek-Fossa, B.A., Jones, R., Kamat, A.M., Khoo, V., Kiltie, A.E., Krege, S., Ladoire, S., Lara, P.C., Leliveld, A., Linares-Espinós, E., Løgager, V., Lorch, A., Loriot, Y., Meijer, R., Carmen Mir, M., Moschini, M., Mostafid, H., Müller, A.-C., Müller, C.R., N’Dow, J., Necchi, A., Neuzillet, Y., Oddens, J.R., Oldenburg, J., Osanto, S., Oyen, W.J.G., Pacheco-Figueiredo, L., Pappot, H., Patel, M.I., Pieters, B.R., Plass, K., Remzi, M., Retz, M., Richenberg, J., Rink, M., Roghmann, F., Rosenberg, J.E., Rouprêt, M., Rouvière, O., Salembier, C., Salminen, A., Sargos, P., Sengupta, S., Sherif, A., Smeenk, R.J., Smits, A., Stenzl, A., Thalmann, G.N., Tombal, B., Turkbey, B., Vahr Lauridsen, S., Valdagni, R., Van Der Heijden, A.G., Van Poppel, H., Vartolomei, M.D., Veskimäe, E., Vilaseca, A., Vives Rivera, F.A., Wiegel, T., Wiklund, P., Williams, A., Zigeuner, R., and Witjes, J.A.

Published
2019
Full Text
View/download PDF

4. Current best practice for bladder cancer: a narrative review of diagnostics and treatments

Author

Compérat, E., Amin, M.B., Cathomas, R., Choudhury, A., Santis, M. de, Kamat, A., Stenzl, A., Thoeny, H.C., and Witjes, J.A.

Subjects
Urinary Bladder Neoplasms, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Neoplasm Invasiveness, General Medicine, 610 Medicine & health
Abstract

Item does not contain fulltext This Seminar presents the current best practice for the diagnosis and management of bladder cancer. The scope of this Seminar ranges from current challenges in pathology, such as the evolving histological and molecular classification of disease, to advances in personalised medicine and novel imaging approaches. We discuss the current role of radiotherapy, surgical management of non-muscle-invasive and muscle-invasive disease, highlight the challenges of treatment of metastatic bladder cancer, and discuss the latest developments in systemic therapy. This Seminar is intended to provide physicians with knowledge of current issues in bladder cancer.

Published
2022

5. Non-seminomatous testicular germ cell tumours with teratoma-free primaries exhibit a superior early relapse-free survival

Author

Paffenholz, P., primary, Landwehr, G., additional, Seidel, C., additional, Poch, A., additional, Bokemeyer, C., additional, Cathomas, R., additional, Pongratanakul, P., additional, Hiester, A., additional, Albers, P., additional, Pichler, M., additional, Krege, S., additional, Syring-Schmandke, I., additional, Heinzelbecker, J., additional, Nestler, T., additional, Pfister, D., additional, and Heidenreich, A., additional

Published
2023
Full Text
View/download PDF

7. Treatment outcomes of men with stage 2 non-seminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: A systematic review

Author

Neuenschwander, A., primary, Lonati, C., additional, Antonelli, L., additional, Papachristofilou, A., additional, Cathomas, R., additional, Rothermundt, C., additional, Templeton, A.J., additional, Gulamhusein, A., additional, Fischer, S., additional, Gillessen, S., additional, Hermanns, T., additional, Lorch, A., additional, Agostino, M., additional, and Fankhauser, C.D., additional

Published
2022
Full Text
View/download PDF

9. LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial

Author

Rothermundt, C.A., primary, Cathomas, R., additional, Gysel, K., additional, Fischer, N., additional, Mestre, R. Pereira, additional, Hermanns, T., additional, Rothschild, S.I., additional, Mach, N., additional, Mingrone, W., additional, Ciriolo, M., additional, Müller, B., additional, Erdmann, A.A., additional, Schär, C., additional, Mamot, C., additional, Bohanes, P., additional, Omlin, A.G., additional, Bastian, S., additional, Ribi, K., additional, and Gillessen, S., additional

Published
2022
Full Text
View/download PDF

10. 1454P Optimizing ipilimumab in RCC: Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC

Author

Stenner-Liewen, F., primary, Cathomas, R., additional, Rothermundt, C.A., additional, Beyer, J., additional, Mach, N., additional, Zihler, D., additional, Erdmann, A.A., additional, Kueng, M., additional, Dietrich, D., additional, Glaus Garzon, J., additional, Lorch, A., additional, Berthold, D.R., additional, and Läubli, H., additional

Published
2022
Full Text
View/download PDF

12. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comperat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmuller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinos E, Logager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Muller AC, Muller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupret M, Rouviere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van der Heijden AG, Van Poppel H, Vartolomei MD, Veskimae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A, Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Der Heijden AGV, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A., UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Witjes, Ja, Babjuk, M, Bellmunt, J, Bruins, Hm, De Reijke, Tm, De Santis, M, Gillessen, S, James, N, Maclennan, S, Palou, J, Powles, T, Ribal, Mj, Shariat, Sf, Van der Kwast, T, Xylinas, E, Agarwal, N, Arends, T, Bamias, A, Birtle, A, Black, Pc, Bochner, Bh, Bolla, M, Boormans, Jl, Bossi, A, Briganti, A, Brummelhuis, I, Burger, M, Castellano, D, Cathomas, R, Chiti, A, Choudhury, A, Comperat, E, Crabb, S, Culine, S, De Bari, B, De Blok, W, De Visschere, Pjl, Decaestecker, K, Dimitropoulos, K, Dominguez-Escrig, Jl, Fanti, S, Fonteyne, V, Frydenberg, M, Futterer, Jj, Gakis, G, Geavlete, B, Gontero, P, Grubmuller, B, Hafeez, S, Hansel, De, Hartmann, A, Hayne, D, Henry, Am, Hernandez, V, Herr, H, Herrmann, K, Hoskin, P, Huguet, J, Jereczek-Fossa, Ba, Jones, R, Kamat, Am, Khoo, V, Kiltie, Ae, Krege, S, Ladoire, S, Lara, Pc, Leliveld, A, Linares-Espinos, E, Logager, V, Lorch, A, Loriot, Y, Meijer, R, Mir, Mc, Moschini, M, Mostafid, H, Muller, Ac, Muller, Cr, N'Dow, J, Necchi, A, Neuzillet, Y, Oddens, Jr, Oldenburg, J, Osanto, S, Oyen, Wjg, Pacheco-Figueiredo, L, Pappot, H, Patel, Mi, Pieters, Br, Plass, K, Remzi, M, Retz, M, Richenberg, J, Rink, M, Roghmann, F, Rosenberg, Je, Roupret, M, Rouviere, O, Salembier, C, Salminen, A, Sargos, P, Sengupta, S, Sherif, A, Smeenk, Rj, Smits, A, Stenzl, A, Thalmann, Gn, Tombal, B, Turkbey, B, Lauridsen, Sv, Valdagni, R, Van der Heijden, Ag, Van Poppel, H, Vartolomei, Md, Veskimae, E, Vilaseca, A, Rivera, Fav, Wiegel, T, Wiklund, P, Williams, A, Zigeuner, R, and Horwich, A

Subjects
Treatment, Consensus, Follow-up, education, Bladder cancer, Diagnosis, Consensu, Delphi, Diagnosi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.Setting: Online Delphi survey and consensus conference.Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as >= 70% agreement and

Published
2020

15. Treatment outcomes for men with stage 2 non-seminoma undergoing primary RetroPeritoneal Lymph Node Dissection (RPLND): A systematic review

Author

Neuenschwander, A., primary, Lonati, C., additional, Papachristofilou, A., additional, Cathomas, R., additional, Rothermund, C., additional, Templeton, A.J., additional, Gulamhusein, A., additional, Fischer, S., additional, Gillessen, S., additional, Hermanns, T., additional, Mattei, A., additional, Lorch, A., additional, and Fankhauser, C.D., additional

Published
2022
Full Text
View/download PDF

16. Earlier detection of recurrences using serum micro-RNA371 during active surveillance in men with stage I testicular germ cell tumours

Author

Fankhauser, C.D., primary, Christiansen, A., additional, Rothermundt, C., additional, Cathomas, R., additional, Wettstein, M.S., additional, Grossmann, N.C., additional, Grogg, J.B., additional, Templeton, A.J., additional, Hirschi-Blickenstorfer, A., additional, Lorch, A., additional, Gillessen, S., additional, Moch, H., additional, Beyer, J., additional, and Hermanns, T., additional

Published
2021
Full Text
View/download PDF

19. LBA30 Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10

Author

Papachristofilou, A., primary, Bedke, J., additional, Hayoz, S., additional, Schratzenstaller, U., additional, Pless, M., additional, Hentrich, M., additional, Krege, S., additional, Lorch, A., additional, Aebersold, D.M., additional, Putora, P-M., additional, Berthold, D.R., additional, Zihler, D., additional, Azinwi, N.C., additional, Zengerling, F., additional, Dieing, A., additional, Mueller, A-C., additional, Schaer, C., additional, Biaggi, C., additional, Gillessen, S., additional, and Cathomas, R., additional

Published
2021
Full Text
View/download PDF

20. LBA26 Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16)

Author

Cathomas, R., primary, Procopio, G., additional, Hayoz, S., additional, Kremer, E.A., additional, Kienle, D., additional, Caffo, O., additional, Lorente, D., additional, Pedrazzini, A., additional, Roubaud, G., additional, Nenan, S., additional, Omlin, A.G., additional, Buttigliero, C., additional, Pereira Mestre, R.J., additional, Ribi, K., additional, and Gillessen, S., additional

Published
2021
Full Text
View/download PDF

21. P157 - Real world evidence from a retrospective multi-center analysis for the combination immunotherapy ipilimumab and nivolumab as first-line treatment in advanced renal cell carcinoma

Author

Materna, L., Schlack, K., Stelmach, R., Zschäbitz, S., Neuberger, S., Aydogdu, C., Casuscelli, J., Egenolf, T., Silberg, M., Steinestel, J., Strauss, A., Kirchhoff, F., Ahrens, M., Paffenholz, P., Cathomas, R., Gossler, C., Ivanyi, P., Rehlinghaus, M., Hilser, T., and Grünwald, V.

Published
2023
Full Text
View/download PDF

27. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

Author

Witjes, J.A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. De Blok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Mir, M.C. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Lauridsen, S.V. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Rivera, F.A.V. Wiegel, T. Wiklund, P. Willemse, P.-P.M. Williams, A. Zigeuner, R. Horwich, A.

Abstract

The authors regret that a co-author was mistakenly missed from the authorship. The following co-author should have been included in the authorship: Peter-Paul M. Willemse Department of Oncological Urology, University Medical Center, Utrecht Cancer Center, Utrecht, The Netherlands © 2019 European Society of Medical Oncology and European Association of Urology

Published
2020

28. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A.

Subjects
Consensus, Follow-up, education, Bladder cancer, Diagnosis, Treatment, Delphi
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.

Published
2020

30. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

Author

Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claen, J., Cohn-Cedermark, G., Dahl, A. A., Daugaard, G., De Giorgi, U., De Santis, M., De Wit, M., De Wit, R., Dieckmann, K. P., Fenner, M., Fizazi, K., Flechon, A., Fossa, S. D., Germá Lluch, J. R., Gietema, J. A., Gillessen, S., Giwercman, A., Hartmann, J. T., Heidenreich, A., Hentrich, M., Honecker, F., Horwich, A., Huddart, R. A., Kliesch, S., Kollmannsberger, C., Krege, S., Laguna, M. P., Looijenga, L. H. J., Lorch, A., Lotz, J. P., Mayer, F., Necchi, A., Nicolai, N., Nuver, J., Oechsle, K., Oldenburg, J., Oosterhuis, J. W., Powles, T., Rajpert-De Meyts, E., Rick, O., Rosti, G., Salvioni, R., Schrader, M., Schweyer, S., Sedlmayer, F., Sohaib, A., Souchon, R., Tandstad, T., Winter, C., and Wittekind, C.

Published
2013
Full Text
View/download PDF

34. 1867P Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents: A real-world cross-sectional study from Switzerland (SAKK 95/16)

Author

Ribi, K., primary, Thuerlimann, B.J.K., additional, Schär, C., additional, Dietrich, D., additional, Cathomas, R., additional, Zuerrer, U., additional, Von Briel, T., additional, Anchisi, S., additional, Bohanes, P., additional, Blum, V., additional, von Burg, P., additional, Mannhart, M., additional, Caspar, C.B., additional, von Moos, R., additional, and Mark, M.T., additional

Published
2020
Full Text
View/download PDF

36. Radical cystectomy: The significance of hospital volume and surgeon volume. A systematic review and recommendations by the EAU MIBC Guideline Panel

Author

Bruins, H.M., primary, Veskimae, E., additional, Hernandez, V., additional, Neuzillet, Y., additional, Rouanne, M., additional, Cathomas, R., additional, Compérat, E.M., additional, Cowan, N.C., additional, Gakis, G., additional, Espinós, E.L., additional, Lorch, A., additional, Ribal, M.J., additional, Thalmann, G.N., additional, Yuan, Y., additional, Van Der Heijden, A.G., additional, and Witjes, J.A., additional

Published
2020
Full Text
View/download PDF

37. Prognostic factors in metastatic seminomatous germ cell tumours and elevated human chorionic gonadotrophin (HCG): A study of the G3

Author

Seidel, C., primary, Daugaard, G., additional, Nestler, T., additional, Tryakin, A., additional, Fankhauser, C.D., additional, Hermanns, T., additional, Aparicio, J., additional, Heinzelbecker, J., additional, Pfaffenholz, P., additional, De Giorgi, U., additional, Cathomas, R., additional, Lorch, A., additional, Fingerhut, A., additional, Gayer, F., additional, Bremmer, F., additional, Giannatempo, P., additional, Necchi, A., additional, Aurilio, G., additional, Oing, C., additional, and Bokemeyer, C., additional

Published
2019
Full Text
View/download PDF

40. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Author

Horwich, A. Babjuk, M. Bellmunt, J. Bruins, H.M. De Reijke, T.M. De Santis, M. Gillessen, S. James, N. Maclennan, S. Palou, J. Powles, T. Ribal, M.J. Shariat, S.F. Van Der Kwast, T. Xylinas, E. Agarwal, N. Arends, T. Bamias, A. Birtle, A. Black, P.C. Bochner, B.H. Bolla, M. Boormans, J.L. Bossi, A. Briganti, A. Brummelhuis, I. Burger, M. Castellano, D. Cathomas, R. Chiti, A. Choudhury, A. Compérat, E. Crabb, S. Culine, S. De Bari, B. DeBlok, W. De Visschere, P.J.L. Decaestecker, K. Dimitropoulos, K. Dominguez-Escrig, J.L. Fanti, S. Fonteyne, V. Frydenberg, M. Futterer, J.J. Gakis, G. Geavlete, B. Gontero, P. Grubmüller, B. Hafeez, S. Hansel, D.E. Hartmann, A. Hayne, D. Henry, A.M. Hernandez, V. Herr, H. Herrmann, K. Hoskin, P. Huguet, J. Jereczek-Fossa, B.A. Jones, R. Kamat, A.M. Khoo, V. Kiltie, A.E. Krege, S. Ladoire, S. Lara, P.C. Leliveld, A. Linares-Espinós, E. Løgager, V. Lorch, A. Loriot, Y. Meijer, R. Carmen Mir, M. Moschini, M. Mostafid, H. Müller, A.-C. Müller, C.R. N'Dow, J. Necchi, A. Neuzillet, Y. Oddens, J.R. Oldenburg, J. Osanto, S. Oyen, W.J.G. Pacheco-Figueiredo, L. Pappot, H. Patel, M.I. Pieters, B.R. Plass, K. Remzi, M. Retz, M. Richenberg, J. Rink, M. Roghmann, F. Rosenberg, J.E. Rouprêt, M. Rouvière, O. Salembier, C. Salminen, A. Sargos, P. Sengupta, S. Sherif, A. Smeenk, R.J. Smits, A. Stenzl, A. Thalmann, G.N. Tombal, B. Turkbey, B. Vahr Lauridsen, S. Valdagni, R. Van Der Heijden, A.G. Van Poppel, H. Vartolomei, M.D. Veskimäe, E. Vilaseca, A. Vives Rivera, F.A. Wiegel, T. Wiklund, P. Williams, A. Zigeuner, R. Witjes, J.A.

Subjects
education
Abstract

Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach. © 2019 European Society for Medical Oncology

Published
2019

43. Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway

Author

Schuler, Martin, Cassier, P., Penel, N., Cathomas, R., Richly, Heike, Schostak, M., Janitzky, A., Wermke, M., Nogova, L., Tai, D., Sayehli, C., Grüllich, C., Grande, E., Navarro, A., Park, S. H., Nogai, H., Bender, S., Ellinghaus, P., and Joerger, M.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2018

44. Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)

Author

von Moos, R., primary, Hawle, H., additional, Hayoz, S., additional, Cathomas, R., additional, Müller, A., additional, Schmid, S., additional, Pagani, O., additional, Wehrhahn, T., additional, Rauch, D., additional, Anchisi, S., additional, Hermanns, T., additional, Fehr, M., additional, Stoll, S., additional, Bützberger, P., additional, Zweifel, M., additional, Huber, U., additional, Fuhrer, A.C., additional, Schär, C., additional, Gillessen, S., additional, and Templeton, A.J., additional

Published
2018
Full Text
View/download PDF

46. CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)

Author

Rothschild, S, Amrein, Michael, Riether, Carsten, Gautschi, O, Schuster, N, Li, Q, Savic, S, Schneider, M, Biaggi, C, Bubendorf, L, Brutsche, M, Zippelius, A, Zander, T, Betticher, D, Früh, M, Stahel, R, Cathomas, R, Rauch, Daniel, Pless, M, Ochsenbein, Adrian, and Jaggi, R

Subjects
610 Medicine & health
Published
2017
Full Text
View/download PDF

47. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up

Author

Honecker, F., primary, Aparicio, J., additional, Berney, D., additional, Beyer, J., additional, Bokemeyer, C., additional, Cathomas, R., additional, Clarke, N., additional, Cohn-Cedermark, G., additional, Daugaard, G., additional, Dieckmann, K.-P., additional, Fizazi, K., additional, Fosså, S., additional, Germa-Lluch, J.R., additional, Giannatempo, P., additional, Gietema, J.A., additional, Gillessen, S., additional, Haugnes, H.S., additional, Heidenreich, A., additional, Hemminki, K., additional, Huddart, R., additional, Jewett, M.A.S., additional, Joly, F., additional, Lauritsen, J., additional, Lorch, A., additional, Necchi, A., additional, Nicolai, N., additional, Oing, C., additional, Oldenburg, J., additional, Ondruš, D., additional, Papachristofilou, A., additional, Powles, T., additional, Sohaib, A., additional, Ståhl, O., additional, Tandstad, T., additional, Toner, G., additional, and Horwich, A., additional

Published
2018
Full Text
View/download PDF

48. Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

Author

Rentsch, C., primary, Bosshard, P., additional, Mayor, G., additional, Rieken, M., additional, Püschel, H., additional, Wirth, G., additional, Cathomas, R., additional, Grode, L., additional, Parzmair, G., additional, Eisele, B., additional, Sharma, H., additional, Shaligram, U., additional, Goldenberger, D., additional, Spertini, F., additional, Audran, R., additional, Enoui, M., additional, Berardi-Vilei, S., additional, Hayoz, S., additional, and Wicki, A., additional

Published
2018
Full Text
View/download PDF

50. MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)

Author

Rothschild, S., primary, Amrein, M., additional, Riether, C., additional, Gautschi, O., additional, Schuster, N., additional, Li, Q., additional, Savic, S., additional, Schneider, M., additional, Biaggi, C., additional, Bubendorf, L., additional, Brutsche, M., additional, Zippelius, A., additional, Zander, T., additional, Betticher, D., additional, Früh, M., additional, Stahel, R., additional, Cathomas, R., additional, Rauch, D., additional, Pless, M., additional, Ochsenbein, A., additional, and Jaggi, R., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results